Last updated: October 01, 2026

Application No. 18/343,968

NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOF

Final Rejection

Filed

Jun 29, 2023

Priority

Jan 31, 2017 — provisional 62/452,963 +7 more

Examiner

DEVI, SARVAMANGALA

Art Unit

1645

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Pfizer Inc.

OA Round

4 (Final)

Interview Optional

— +55.3% interview lift. Interview already conducted in this application's prosecution history. This examiner has a 65% grant rate with +55.3% interview lift. Since an interview has already been tried, recommend written response with narrowed claims based on precedent claim evolution patterns.

Based on 877 resolved cases, 2023–2026

Examiner Intelligence

DEVI, SARVAMANGALA View full profile →

Grants 65% — above average

Career Allowance Rate

573 granted / 877 resolved

+5.3% vs TC avg

Strong +55% interview lift

Without

With

+55.3%

Interview Lift

resolved cases with interview

Typical timeline

3y 4m

Avg Prosecution

49 currently pending

Career history

934

Total Applications

across all art units

Statute-Specific Performance

§101

7.2%

-32.8% vs TC avg

§103

17.7%

-22.3% vs TC avg

§102

25.4%

-14.6% vs TC avg

§112

43.3%

+3.3% vs TC avg

Black line = Tech Center average estimate • Based on career data from 877 resolved cases

Prosecution Timeline

Show 3 earlier events

May 29, 2025

Examiner Interview (Telephonic)

May 29, 2025

Examiner Interview Summary

Jul 14, 2025

Final Rejection mailed

Oct 14, 2025

Request for Continued Examination

Oct 15, 2025

Response after Non-Final Action

Nov 19, 2025

Non-Final Rejection mailed

Mar 19, 2026

Response Filed

Jun 24, 2026

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/261,975

Patent 12697379

PEGYLATED TETANUS NEUROTOXINS AND TREATMENT OF HYPOTONIA

5y 6m to grant Granted Aug 04, 2026

17/602,628

Patent 12699090

DIAGNOSTIC REAGENTS

4y 10m to grant Granted Aug 04, 2026

18/530,348

Patent 12691167

PROTEINS AND IMMUNIZING COMPOSITIONS CONTAINING KLEBSIELLA PROTEINS AND METHODS OF USE

2y 7m to grant Granted Jul 28, 2026

17/757,972

Patent 12667611

NEW USE OF BCG IMMUNOGENIC FORMULATION EXPRESSING A RESPIRATORY SYNCITIAL VIRUS PROTEIN AGAINST hMPV

4y 0m to grant Granted Jun 30, 2026

18/425,772

Patent 12661411

MONOCLONAL ANTIBODY AND VACCINE TARGETING FILAMENTOUS BACTERIOPHAGE

2y 4m to grant Granted Jun 23, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6

Expected OA Rounds

65%

Grant Probability

99%

With Interview (+55.3%)

3y 4m (~0m remaining)

Median Time to Grant

High

PTA Risk

Based on 877 resolved cases by this examiner. Grant probability derived from career allowance rate.